Pacific Biosciences/$PACB
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Pacific Biosciences
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
- Ticker
- $PACB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 485
- Headquarters
- Menlo Park, United States
- Website
- www.pacb.com
PACB Metrics
BasicAdvanced
$880M
-
-$0.43
2.31
-
Price and volume
Market cap
$880M
Beta
2.31
52-week high
$3.44
52-week low
$1.07
Average daily volume
18M
Financial strength
Current ratio
4.922
Quick ratio
3.895
Long term debt to equity
-21.219
Total debt to equity
-21.351
Interest coverage (TTM)
-72.13%
Profitability
EBITDA (TTM)
-514.995
Gross margin (TTM)
29.42%
Net profit margin (TTM)
-82.49%
Operating margin (TTM)
-111.47%
Effective tax rate (TTM)
-0.63%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
-14.07%
Return on equity (TTM)
-929.32%
Valuation
Price to revenue (TTM)
5.416
Price to book
-26.48
Price to tangible book (TTM)
-2.42
Price to free cash flow (TTM)
-6.611
Free cash flow yield (TTM)
-15.13%
Free cash flow per share (TTM)
-0.428
Growth
Revenue change (TTM)
2.02%
Earnings per share change (TTM)
-76.44%
3-year revenue growth (CAGR)
2.91%
10-year revenue growth (CAGR)
5.87%
3-year earnings per share growth (CAGR)
-31.76%
10-year earnings per share growth (CAGR)
-0.66%
What the Analysts think about PACB
Analyst ratings (Buy, Hold, Sell) for Pacific Biosciences stock.
Analyst projections of the future price of Pacific Biosciences stock.
Bulls say / Bears say
SPRQ-Nx lets customers reuse SMRT Cells and lowers PacBio’s listed whole-genome sequencing price to $345, potentially making HiFi more attractive for larger projects. The new chemistry also adds methylation detection and an AI-powered consensus algorithm. (PacBio)
Clinical use is gaining traction: clinical shipments rose 67% year on year in Q2, and a study in the New England Journal of Medicine found HiFi sequencing effective as a first-tier test for rare-disease diagnosis. This could support wider adoption beyond research labs. (Stock Analysis, PacBio)
PacBio has started sequencing samples for Basecamp Research’s large-scale programme and shipped multiple Revio systems to a new population-scale customer. If these programmes expand, they could bring demand beyond the company’s traditional research customers. (PacBio)
Revenue remains stagnant: Q2 sales fell 2% year on year, and PacBio cut its 2026 revenue outlook to $155–165 million from $165–175 million. That leaves little evidence yet that new products are translating into near-term growth. (PacBio)
The company is still losing substantial cash: it reported a $44.7 million GAAP net loss in Q2, while cash and investments fell to $236.9 million from $314.7 million at year-end. Management now expects cash-flow break-even in 2028, later than its previous end-2027 target. (PacBio, Stock Analysis)
Instrument demand and margins remain under pressure: Vega placements fell to 26 from 38 a year earlier, while annualised Revio consumables pull-through declined to about $202,000 from $219,000. Higher computing and memory costs and lower prices on some Revio orders also weighed on Q2 gross margin. (PacBio)
Data summarised monthly by Lightyear AI. Last updated on 27 Oct 2026.
PACB Financial Performance
Revenues and expenses
PACB Earnings Performance
Company profitability
Upcoming events
No upcoming events
PACB News
AllArticlesVideos
Funds containing PACB
Fund name | Fund size | $PACB weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.07% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.07% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.07% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.05% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.